Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Optimizing MRI techniques for studying memory disorders

Official title: Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases at Inserm U1237 NeuroPresage Team, Cyceron Center in Caen

Run by University Hospital, Caen · NCT05929144 · Data updated 2026-11-12

This study is testing new MRI techniques to see if they can help doctors better understand and diagnose memory disorders in patients.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity Hospital, Caen
Academic / other
Locations1 site (Caen)
StatusRecruiting
StartedMay 5, 2023
Main results expectedJuly 2028
Study endsJuly 2028
Registry record updatedJuly 3, 2023
Trial IDNCT05929144 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are healthy volunteers of legal age who are affiliated with a social security scheme.

Probably not a fit

Patients with chronic neurological or psychiatric conditions, or those with a history of brain disease, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on enhancing MRI sequences used to investigate neurodegenerative diseases and memory disorders. The Inserm NeuroPresage team aims to utilize a new 3T MRI camera to improve image quality and reduce acquisition time. By testing various MRI sequences, the study seeks to optimize these techniques for future research on cognitive deficits and early diagnosis in patients. The findings could lead to better diagnostic tools and understanding of memory-related conditions.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic capabilities for neurodegenerative diseases and memory disorders.

How similar studies have gone: Other studies have shown success in optimizing MRI techniques for various conditions, indicating potential for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Healthy volunteers of legal age
* Affiliation with a social security scheme or beneficiary of such a scheme
* Signing of the protocol informed consent
* For women of childbearing age or capacity, a urine pregnancy test before inclusion

Exclusion Criteria:

* Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women
* Presence of contraindications to MRI examination without contrast agents injection
* Presence of a chronic neurological or psychiatric condition (including substance use disorder)
* History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)
* Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)

Where it's running

  • GIP Cyceron
    Caen, France
    Recruiting

Study contacts

  • Principal investigator: Nicolas Cabé, MD, PhD — CHU Caen Normandie
  • Study coordinator: Géraldine Poisnel, PhD
  • Email: poisnel@cyceron.fr
  • Phone: 0231470206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.